

Bay Area Life Science Report

Q2 2024



Market Overview



The Bay Area Life Science Market

Amidst the growing global life science industry, Bay Area's life science hubs stand out—from the innovation-rich Peninsula to the vibrant East Bay, the entrepreneurial spirit of Silicon Valley, and the scientific tapestry of San Francisco.

The **Peninsula**, situated between San Francisco and Silicon Valley, is a nexus of innovation in the life science sector. Cities like South San Francisco, often referred to as the "Birthplace of Biotechnology," host a concentration of biotech companies and research facilities. The region benefits from its proximity to major airports, leading universities, and a network of industry leaders, making it a strategic location for life science research, development, and collaboration.

The **East Bay** life science market encompasses clusters in Berkeley, Emeryville, Pleasanton, Alameda, Richmond, and Hayward. Major players pharmaceutical manufacturers and a mosaic of startups contribute to innovation and growth, while UC Berkeley serves as a talent powerhouse. Challenges include space limitations and housing shortages, yet the region's waterfront settings, collaborative communities, and strategic locations contribute to its attractiveness for research, development, and industry collaboration. East Bay plays a vital role in the broader Bay Area's global prominence in the life science landscape.

Silicon Valley plays a significant role in the Bay Area's life science sector, boasting a convergence of technology and biopharmaceutical innovation. Renowned for its entrepreneurial spirit, Silicon Valley hosts a multitude of life science startups and established companies working at the intersection of technology and healthcare. The region's access to venture capital, cutting-edge research facilities, and a collaborative ecosystem contribute to its status as a crucial player in life sciences.


San Francisco stands as a major hub for life science advancements, housing a diverse range of biotech, pharmaceutical, and medical research companies. The city's proximity to leading research institutions, such as UCSF, fosters a rich environment for scientific collaboration. San Francisco is home to numerous biotech startups and established firms, contributing to the city's vibrant life science ecosystem.

Collectively, these areas form a comprehensive and interconnected network within the broader Bay Area, each contributing to the region's prominence in the global life science landscape.



Employment

Total Life Science Employment in the Bay Area



Silicon Valley SF Peninsula San Francisco East Bay


Total life science employment has grown steadily over the past 20 years.

In recent years, employment in the life science sector has surged across the San Francisco Bay Area, with Silicon Valley leading the pack, followed by the East Bay, SF Peninsula, and San Francisco proper. This region-wide growth underscores the Bay Area's position as a premier destination for biotechnology and pharmaceutical careers. With each subregion providing a unique contribution to the life science ecosystem, professionals across various fields within the industry find ample opportunities for career advancement and innovation.

Source: Bureau of Labor Statistics

Job Postings

Average Monthly Life Science Job Postings in the Bay Area



Life science hiring has slowed down recently.

Amidst dwindled funding and diminished investor enthusiasm, many life science companies have reduced their hiring efforts.


The surge in life science hiring witnessed in the early half of 2022 significantly decreased into 2023. However, the continues the rebound from the start of the year from the multi-year low that we saw at the end of 2024.

Source: EMSI

Education

Top California Universities For Biological & Biomedical Studies

2021-2022, Degrees awarded for Bachelor's, Master's, and Doctorates




The Bay Area is in no shortage of educated talent.


UC Berkeley and San Francisco State University stand prominently among the top ten colleges in California for the highest number of graduates in Biological & Biomedical studies. Serving as vital contributors, these institutes remain the lifeblood of the life science industry across the Bay Area. Their substantial output of skilled professionals plays a pivotal role in shaping the region's distinctive identity as a hub for innovation and sustained growth in the field of life sciences.

Source: National Center for Education Statistics


Bay Area Market Stats



Absorption



Pricing (Direct NNN)



The life science market has slowed down.

As we transition from the COVID-19 pandemic to a period marked by higher interest rates and economic uncertainty, the fervor that once propelled the life science market has subsided. Initially buoyed by the urgent search for treatments, vaccines, and diagnostics, this industry experienced a surge, amplified by low interest rates and heightened risk appetite among investors during the pandemic—a perfect storm for life sciences.

In response, developers swiftly delivered cutting-edge life science developments and repurposed underperforming office spaces. However, the current scenario reflects a stark shift, catching many developers off guard. Leasing activity has decelerated, primarily due to dwindling funding for life science companies, posing a risk of short-term oversupply in the Bay Area life science market. The looming challenge is navigating a market that is grappling with an influx of space set to arrive in the coming years.

Bay Area Market Stats

	Inventory			Availability			Vacancy			Net Absorption		Leasing Activity		Asking Rent	
	Existing inventory	Deliveries	Under development	Pre-leased %	Direct	Sublet	Total	Direct	Sublet	Total	QTD	YTD	QTD	YTD	Direct NNN/month
SF Peninsula	22,877,767	996,011	3,677,136	32.6%	6,402,212	1,986,917	8,385,228	15.9%	5.4%	21.3%	-54,147	-204,233	89,823	192,092	\$7.19
East Bay	13,496,788	0	1,687,888	68.1%	3,218,974	801,964	4,020,838	14.7%	3.8%	18.5%	165,173	8,289	133,320	210,455	\$3.71
Silicon Valley	3,530,750	0	1,211,000	100%	350,961	199,899	550,860	9.2%	4.1%	13.3%	-24,506	-24,084	-	1,264	\$7.00
San Francisco	2,715,859	0	212,796	0%	1,362,965	630,889	1,993,854	40.0%	19.0%	59.0%	-260,143	-223,684	5,953	25,273	-
Bay Area Total	42,514,068	996,011	6,788,820	53.0%	11,335,112	3,619,569	14,950,780	16.5%	5.6%	22.1%	-173,623	-443,712	229,096	429,084	\$5.33

Subleases

Many life science companies experiencing financial struggles amidst decreasing funding have decided to sublease their life science space. Subleases now make up over 3 million square feet and 30% of total vacancies. Companies on a budget will find unique opportunities for bargain pre-furnished and move-in ready space.

Major Sublease Availabilities in the Bay Area


Sublessor	Location	Available Square Feet	Floors	Term	
FibroGen	409 Illinois St, San Francisco	235,000	1-6	Nov 2028	
	1800 Owens St, San Francisco	225,969	3-7, 9	Negotiable	
RESILIENCE	800 Corporate Way, Fremont	152,995	1	May 2030	
NEKTAR [°]	455 Mission Bay Blvd South, San Francisco	131,223	1-5	Negotiable	
Sangamo	7000 Marina Blvd, Brisbane	103,089	1-5	Negotiable	
Allakos 🏁	825 Industrial Rd, San Carlos	93,332	5-6	Negotiable	
Theravance Biopharma	901 Gateway Blvd, South San Francisco	78,070	1-3	Negotiable	

Investments and Funding



NIH Funding

NIH Funds Awarded Annually



Total funding provided by the NIH has nearly doubled in the last decade.

The National Institutes of Health (NIH) serves as a crucial funding source for biomedical and health-related research, influencing the landscape of life science real estate. Its support reaches across a spectrum of organizations, spanning for-profit companies, government agencies, and educational institutions. Through various avenues like grants, contracts, and training programs, the NIH channels funding into entities within the life sciences sector. This financial backing is instrumental in fostering research aimed at developing medicines and discovering cures for a diverse array of illnesses and disabilities.

Source: National Institute of Health

Top NIH Funded Organizations in California

In 2023, UCSF and Stanford University were the top recipients of NIH funding in California, together receiving \$1.5 billion. With the current momentum, 2024 funding is poised to surpass that figure significantly.

Top NIH Funded Organizations in 2024 Year-to-Date ■ Silicon Valley ■ SF Peninsula ■ San Francisco ■ East Bay UCSF UCSF \$789M \$577M Stanford University Stanford University \$629M \$448M UC San Diego UCLA \$580M \$429M UC San Diego UCLA \$389M \$572M University of Southern California University of Southern California \$359M \$237M UC Davis UC Davis \$280M \$219M Scripps Research Institute UC Irvine \$221M \$163M UC Irvine Scripps Research Institute \$211M \$130M UC Berkeley UC Berkeley \$126M \$143M Cedars-Sinai Medical Center Cedars-Sinai Medical Center \$103M \$74M \$0M \$0M \$200M \$400M \$600M \$800M \$200M \$400M \$600M

Top NIH Funded Organizations in 2023

NIH Funding is dated by fiscal year. Source: National Institute of Health

Top NIH Funded For-Profit Organizations in California

In 2023, seven of the top ten for-profit organizations funded by the NIH were in the Bay Area. That has heavily receded in the first half of 2024, just two of the ten has been for the Bay Area.

Top NIH Funded For-Profits in 2024 Year-to-Date


■ Silicon Valley ■ SF Peninsula ■ San Francisco ■ East Bay Hungry Heart Media Lawrence Berkeley Lab \$32.2M \$9.6M Lawrence Berkeley Lab \$22.9M Hungry Heart Media \$7.8M Color Health **BioCorRx Pharmaceuticals** \$13.7M \$4.1M **Aligos Therapeutics** \$8.5M Arima Genomics \$3.0M CSS Associates Trethera Corporation \$5.5M \$3.0M SiteOne Therapeutics Vivreon Biosciences \$5.3M \$2.9M Revagenix Spatial Genomics \$5.1M \$2.6M Arisan Therapeutics **Big Eye Diagnostics** \$4.8M \$2.6M Sorrento Therapeutics Care.Coach Corporation \$4.6M \$2.4M Lawrence Livermore Nat. Sec. EicOsis \$4.5M \$2.1M \$20M \$0M \$10M \$30M \$0M \$4M \$8M \$12M

Top NIH Funded For-Profits in 2023

NIH Funding is dated by fiscal year. Source: National Institute of Health

Bay Area Venture Capital Funding

Funding for Biotechnology Research and Development



Source: Crunchbase

Venture capitalist interest in life sciences have fallen in recent quarters.

The COVID-19 pandemic triggered an intense pursuit for cures, vaccines, and treatments, casting a halo effect over the entire life science industry. This fervor, coupled with historically low interest rates driving investors toward unprecedented risk-taking, set the stage for a potential bubble in the life science market.

As we transitioned out of the pandemic into an era of elevated interest rates amid economic uncertainty, investors have adopted a more cautious, risk-off approach. The appetite for high-risk investments, particularly in biopharmaceuticals, has notably diminished, leading to a significant decline in venture capitalist funding in this sector.

Nevertheless, the first quarter of 2024 shows a rebound in funding compared to the previous quarter, which marked the secondlowest funded quarter since the start of the pandemic. This uptick may signal a resurgence in investor interest in the life science sector.

Top VC Funded Bay Area Companies

In recent times, there has been a notable shift in life science venture capitalist funding, moving away from the East Bay and gravitating towards the Peninsula and Silicon Valley.

■ Silicon Valley ■ SF Peninsula ■ San Francisco ■ East Bay Cellares Marea Therapeutics \$255M \$255M HeartFlow Freenome \$215M \$254M AltruBio **CARGO** Therapeutics \$225M \$200M **Terremoto Biosciences** BillionToOne \$130M \$175M Neurona Therapeutics **Carmot Therapeutics** \$120M \$150M Noah Medical **Rakuten Medical** \$150M \$119M Firefly Bio **Kriya Therapeutics** \$150M \$94M **Bitterroot Bio** R3 Vascular \$87M \$145M **Frontier Medicines Eikon Therapeutics** \$106M \$80M **RefleXion Medical** Midi Health \$105M \$60M \$0M \$100M \$200M \$300M \$0M \$100M \$200M \$300M

Top VC Funded Companies in 2023


Top VC Funded Companies in 2024 Year-to-Date

page 15 Bay Area Life Science Report | Q2 2024

Source: Crunchbase

Top VC Funded Life Science Sectors

Funding by Category in Q2 2024



Al-powered life sciences have begun to attract substantial funding.

The COVID-19 pandemic prompted swift government responses, including funding initiatives and expedited regulatory processes for companies developing vaccines, antivirals, and other COVID-19 treatments. This crisis also catalyzed a widespread societal shift towards prioritizing health and wellness.

As a result, the pandemic significantly influenced funding priorities, and its residual effects continue to shape investment decisions in the years to come.

In early 2024, the emergence of commercialized artificial intelligence has permeated the life science industry, garnering considerable funding. With potentially paradigm-shifting potential, the burgeoning field of AI in science will be a crucial subindustry to monitor in the years ahead.

Looking Ahead



Under Construction

Developers seized the opportunity presented by the life science boom during the pandemic, initiating substantial state-of-the-art constructions to capitalize on the heightened demand for life science facilities.

Major Constructions in the Bay Area

Location	Developer	Total Square Feet	Current Availability	Description	Delivery Date
Bayer Campus Expansion 800 Dwight Way, Berkeley	Bayer Healthcare	918,000	0%	The project will demolish nine buildings on Bayer's existing campus to create twelve new buildings for office lab and production.	Q4 2025
Kilroy Oyster Point Phase 2 - Building D, E, F 384 Oyster Point Blvd, South San Francisco	Kilroy Realty Corporation	865,000	100%	Three 7 to 8-story buildings as part of Phase 2 of Oyster Point. Phase 3 is proposed to add another 1 million sf to the Oyster Point project.	Q4 2024
Berkeley Commons 600 Addison St & 601 Bancroft St, Berkeley	Lane Partners	538,825	100%	Two neighboring three-story structures situated on the Berkeley waterfront in close proximity to UC Berkeley's campus.	Q3 2024
The Landing 1699 & 1701 Bayshore Hwy, Burlingame	King Street Properties, Helios Real Estate Partners	503,500	100%	Two 6 to 7-story building accompanied by a 9-story parking garage.	Q4 2025
Alexandria Center for Life Science 30 Rollins Rd & 230 Harriet Tubman Way, Millbrae	Alexandria Real Estate Equities	485,346	41%	Two 6-story buildings, with one more proposed. 230 Harriet Tubman Way is preleased by Eikon Therapeutics and will be delivered in Q4.	Q4 2024- Q1 2025
580 Dubuque Ave, South San Francisco	IQHQ	339,993	100%	8-story building with a four-story underground garage near the new South San Francisco Caltrain station.	Q3 2024
Avia Labs 210 Adrian Rd, Millbrae	Longfellow Real Estate Partners	315,000	100%	6-story building near the Millbrae transit center.	Q4 2025

Trends & Predictions



Short term oversupply

The Bay Area is likely to experience a temporary oversupply of life science space until the latter half of the decade.



Lower rents

As landlords encounter dropping demand and increasing vacancy, rental rates will offer excellent opportunities for life science companies on a budget.



More tenant concession

The current life science market is shifting further and further into the tenant's favor. Landlords are willing to offer more concessions than ever.

₹₽

Focus shifts to healthcare AI

Following the current headlines of artificial intelligence, healthcare AI is getting increasingly more attention. These tenants typically occupy space like conventional tech companies.



More building acquisitions

Similar to the current office market, the life science market is likely to see more sales and acquisitions as distressed landlords struggle to lease their buildings.



Shorter term deals

Life science companies are likely to leverage the slowing market to sign shorter term leases. As-is sublease deals will contribute to this as well.

Looking Ahead

Despite the current challenges facing the Bay Area's life science market, Avison Young's outlook for the future remains optimistic. The imminent influx of under-construction space, though likely to create a short-term oversupply and a slowdown in tenant activity, is seen as a temporary setback for owners and investors.

Looking ahead, as the economy rebounds in the latter half of the 2020s and investor confidence returns, the substantial growth in state-of-the-art life science inventory within the Bay Area presents a unique opportunity. The slow current activity sets the stage for start-up life science companies to capitalize on lower rents and favorable leasing conditions, providing them with unprecedented access to premium spaces. Investors seeking to optimize their returns will discover that life science real estate presents once-in-a-lifetime bargains.

The enduring fundamentals that make the Bay Area a beacon of innovation and growth have proven resilient even in the face of the toughest crises. With world-class universities set against a backdrop of stunning landscapes featuring beaches and redwood forests, the Bay Area continues to be an irresistible magnet for top talent from around the globe. As we navigate through the present challenges, the region remains poised for a robust resurgence and sustained growth in the life science sector.



For more market insights and information visit **avisonyoung.com**

Tim Hogan

Will O'Daly

Principal +1 415 301 3183 tim.hogan@avisonyoung.com CA Lic # 01375367

Associate +1 650 703 8336 will.odaly@avisonyoung.com CA Lic # 02063132

Howard Huang

Market Intelligence Analyst - Northern California +1 510 254 4261 howard.huang@avisonyoung.com



© 2023 Avison Young. All rights reserved. E. & O.E.: The information contained herein was obtained from sources which we deem reliable and, while thought to be correct, is not guaranteed by Avison Young.